Pharmaceutical composition for treating ear diseases

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine. A composition for treating an ear disease is introduced into the tympanic cavity, contains a polyoxyethylene-polyoxypropylene copolymer, an active substance specified in an immunomodulator, a vasopressin antagonist, an ion channel antagonist, a neurokinin receptor antagonist, a serotonin reuptake inhibitor, an NMDA-receptor antagonist, a prostaglandin analogue, a preparation having an effect on the central nervous system, a GABA receptor modulator, a cytotoxic agent, an antioxidant, a glutamate receptor modulator or a calcineurin inhibitor.

EFFECT: invention provides the prolonged release of the active substance into the internal ear for a period of time of at least 7 days.

14 cl, 3 dwg, 114 ex

 

The text descriptions are given in facsimile form.

1. Composition for introduction into the drum cavity intended for the treatment of diseases of the ear, including:
the copolymer of polyoxyethylene and polyoxypropylene;
active substance selected from immunomodulator, an antagonist of vasopressin, a modulator of ion channels, receptor antagonist neirokinina, an inhibitor of serotonin reuptake, the modulator of the NMDA receptor, prostaglandin analog, a drug acting on the Central nervous system, the modulator of the GABA receptor, cytotoxic means, an antioxidant, a modulator of glutamate receptor or an inhibitor of calcineurin;
moreover, the composition provides a delayed release of the active substance in the inner ear during the period of time of at least 7 days.

2. The composition according to claim 1, in which the active substance is a drug acting on the Central nervous system.

3. The composition according to claim 2, in which the drug acting on the Central nervous system, is diazepin.

4. The composition according to claim 1, in which the active substance which is a modulator of ion channels.

5. The composition according to claim 4, in which the modulator of ion channels is retigabine.

6. The composition according to claim 1, in which the active ingredient is a modulator of glutamate receptor.

7. The composition according to claim 1, which is acceptable to the ears of thermally reversible gel.

8. The composition according to claim 1 in which the copolymer of polyoxyethylene and polyoxypropylene is poloxamer 407.

9. The composition according to claim 1, which is a liquid suitable for injection with a syringe with a fine needle or cannula.

10. Composition according to any one of claims 1 to 9, optionally containing power penetration.

11. Composition according to any one of claims 1 to 9, in which the active substance is in the form of a free base, salt, prodrug, or combination thereof.

12. Composition according to any one of claims 1 to 9, in which the active substance consists of separate particles.

13. The composition according to item 12, in which the active substance is essentially in the form of micronized particles.

14. The composition according to claim 1, where the disease or condition of the ear is a Meniere's disease, sudden sensorineural hearing loss caused by noise, hearing loss, age-related hearing loss, autoimmune disease of the ear, vertigo or tinnitus.



 

Same patents:

FIELD: medicine, pharmaceutics.

SUBSTANCE: there are presented: pharmaceutical composition for treating an infection containing mometasone furoate or a solvate thereof, Orbifloxacin, a fatty acid containing 3 to 18 carbon atoms and having a melting point of no more than about 60; a method of treating an infection in an animal involving administration thereof, using the above composition for preparing a drug for treating the infection in the animal and a therapeutic kit for treating the infection comprising the above composition. The storage stability of the declared composition at room temperature is shown. The examples of the stable formulations of suspensions, e.g. for treating eye infection are provided.

EFFECT: preparing the pharmaceutical composition for treating the infection.

14 cl, 11 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: intratympanic composition used for treating an ear disease contains: (a) an antimicrobial agent consisting of a number of particles; and (b) a polyoxyethylene and polyoxypropylene copolymer; the composition (i) is a liquid at room temperature; (ii) has a gelling point within the range of 19C to 42C; (iii) has a gel viscosity of 15000 sP to 1000000 sP; (iv) has an osmolarity less than 1000 mOsm/l; and the intratympanic composition release the antimicrobial agent in an ear for at least 5 days, and it is introduced at room temperature.

EFFECT: effective treatment of the ear diseases; the composition is non-toxic and has a non-irritating effect on the ear structures, provides the permanent prolonged release of the active agent with a reduced dose rate and reduces the risk of a potential tympanum damage.

13 cl, 9 tbl, 5 dwg, 30 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to medicine and deals with composition for application in treatment of ear diseases by intra-tympanum introduction into membrane of cochlea window or near membrane of cochlea window, which contains, acceptable for ear treatment thermoreversible water gel, which contains polymer of polyoxypropylene and polyoxyethylene and anti-apoptosis agent, slowed release of anti-apoptosis agent into cochlea taking place for, at least, 4 days.

EFFECT: invention ensures constant, slowed, prolonged release of active agent.

10 cl, 26 ex, 5 dwg

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to otorhinolaryngology, and may be applicable for surgical management of the patients with an ossicular chain pathology. For this purpose, an ossiculoplasty involves graft fixation by a platelet enriched autoblood plasma bunch taken immediately before the operation That is followed by laser coagulation of the bunch.

EFFECT: technique provides improved functional effect and simplified ossiculoplasty, eliminated allergic reactions, eliminated risk of graft rejection, reduced recurrences due to fixation of the repaired elements, reduced risk of dislocation thereof up to formation of the physiological fixation ensured by middle ear soft tissues regeneration.

1 ex

FIELD: medicine.

SUBSTANCE: pharmaceutical composition, suitable for application in treatment of ear diseases includes acceptable for ear thermoreversable water gel. Pharmaceutical composition consists of anti-inflammatory corticosteroid in form of multiple particles and polyoxypropylene and polyoxyethylene-based polymer. Composition is introduced locally to the subject, suffering from ear disease, by intratympanic introduction on membrane of cochlea window or near it.

EFFECT: composition in accordance with invention ensures prolonged release of anti-inflammatory corticosteroid through membrane of cochlea window into inner ear cochlea during, at least, 5 days after a single introduction.

12 cl, 9 dwg, 9 tbl, 31 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely otorhinolaryngology, and may be used in complex therapy of acute othelcosis. Low-frequency ultrasound is used to introduce ceftriaxone phonophoresis through an eardrum into a tympanic cavity for 10 seconds. Then 5 minutes later, it is followed by the phonophoretic introduction of ceftriaxone and lidase in equal proportions into mastoid, preauricular and submandibular lymph nodes for 15 seconds. The therapeutic course is 5 daily procedures.

EFFECT: method provides higher conservative clinical effectiveness in the patients with acute othelcosis ensured by additional pathogenetic lymphotropic exposure on the region of middle ear.

1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions refers to medicine, namely otorhinolaryngology and may be used for treating internal ear disorders. That is ensured by using a 1-aminoalkylcyclohexane derivative specified in neramexane or its pharmaceutically acceptable salt. Said derivative is introduced according to the titration schedule which involves increasing a dose of neramexane and gradually increasing a dose by 25 mg or 12.5 mg every week over a period of four to five weeks to achieve an effective daily dose of 50 to 75 mg. What is also presented is using the 1-aminoalkylcyclohexane derivative specified in neramexane or its pharmaceutically acceptable salt, and a method of treating internal ear disorders in an individual in need thereof.

EFFECT: group of inventions enables the fast and safe achievement of the effective dose of neramexane with side effects herewith minimised.

14 cl, 9 dwg, 10 tbl, 8 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: what is presented is application of a 1-aminoalkyltcyclohexane derivative specified in neramexane or its pharmaceutically acceptable salt for preparing a drug for preventing and/or treating hearing loss, except for drug-induced hearing loss, application thereof for preventing and/or treating hearing loss, except for drug-induced hearing loss and a pharmaceutical composition for the same application.

EFFECT: auditory threshold extension after 4 months of the therapy with neramexane 50 mg a day is shown.

27 cl, 1 dwg, 1 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: group of inventions refers to medicine, namely to otolaryngology, and may be used for treating tinnitus in a person in need thereof. That is ensured by introducing a therapeutically effective dose of a 1-aminoalkylcyclohexane derivative specified in neramexane or its pharmaceutically acceptable salt. The therapeutically effective dose of neramexane is introduced daily for a first period making at least three months and followed by a second period making at least one month. The second period involves introducing neramexane in a dose making 0-75% of the therapeutically effective dose provided when neramexane is not introduced during the second period, the treatment of the first period is repeated after the second period.

EFFECT: group of inventions provides clinical effectiveness in treating and preventing tinnitus, as well as a need of maintenance therapy.

24 cl, 1 dwg, 8 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: nutrient composition contains the nonpathogenic bacterial strain Lactococcus rhamnosus ATCC 53103 or Lactococcus rhamnosus CGMCC 1.3724 able to stimulate a systemic immune response, and the nonpathogenic bacterial strain Micrococcus varians MCV8 or Streptococcus salivarius DSM 13 084 able to have bacteriostatic and bactericidal effect on pathogens related to the onset of otitis, such as Streptococcus pneumoniae, non-typed Haemophilus influenzae and Moraxella catarrhalis The composition contains 104 to 1012 CFU/g of fresh weight of the composition of each strain. The composition additionally contains Streptococcus thermophilus and additionally contains at least one prebiotic in the amount of 0.3 to 6% of composition weight. The composition represents a baby formula or a food additive.

EFFECT: invention provides an effective protection against nasopharyngeal mucosa colonisation with pathogenic bacteria related with the onset of otitis.

7 cl, 1 tbl, 2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: aqueous suspensions contain riluzol or a pharmaceutical acceptable salt, at least one surfactant, and at least one suspending agent. Riluzol is found in the amount of approximately 0.1% to approximately 20% (weight/volume) and characterized by a particle size less than approximately 200 mcm. The surfactant is specified in anionic surfactants, nonionic surfactant or a mixture thereof. The suspending agent is specified in smectic clays, microcrystalline cellulose, natural gums or a mixture thereof.

EFFECT: suspension of riluzol according to the invention are physically and chemically stable, has the common local (oral) anaesthetic effect specific for riluzol.

19 cl, 16 ex

Topical composition // 2497516

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to a topical pharmaceutical composition in the form of an opaque emulsion gel. The composition contains 1.2-4 wt % of diclofenac diethylammonium salt, saturated or unsaturated C10-C18fatty alcohol, at least 40 wt % of water, C2-C4alkanol, glycol solvent, gelling agent, liquid lipid forming an oil phase of the emulsion gel, non-ionic surfactant and agent with the primary properties to reduce pH of the prepared composition to 6-9.

EFFECT: compositions under the invention are characterised by high skin permeability, extremely low systemic absorption, absence of human skin irritation after application, high chemical and physical stability, complete solubility of the active component and considerable relief of pain intensity.

8 cl, 4 tbl, 5 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to chemical-pharmaceutical industry and represents a pharmaceutical composition for treating or preventing AIDS in an orally acceptable presentation containing: 1 to 99 wt % of at least one zeolite, montmorillonite or a mixture thereof as the ingredient F; 1 to 99 wt % of at least raw or dried blue-green algae as the ingredient G; 0 to 50 wt % of conventional pharmaceutical excipients and additives as the ingredient H; the total amount of the ingredients F, G and optionally H makes 100 wt %, with the weight ratio of the ingredients F and G at a dry basis falls within the range of 0.2:1 to 5:1.

EFFECT: invention provides creating a composition for treating or preventing AIDS containing a combination of zeolites and algae drugs.

11 cl, 1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry and represents a gel formulation for wounds and burns of various aetiologies enabling epithelialisation and containing active substances, a base and water, characterised by the fact that as an active substance it contains recombinant interferon specified in a group of recombinant interferon-alpha, recombinant interferon-beta, recombinant interferon-gamma, boric acid and lidocaine hydrochloride, and as a base it contains hydroxyl propyl methylcellulose, and the ingredients are taken in the certain proportions, wt %.

EFFECT: invention provides accelerated wound and burn healing, reduced complications and eliminated pain when applied to the wound.

2 cl, 4 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry and provides an external therapeutic agent for the patients suffering atopic dermatitis comprising zinc pyrithione, urea, glyceryl stearate, emulsion wax, triethanolamine, cocoa butter, corn oil, mineral oil, caprylic and capric acid triglycerides, cyclomethicone, glycerine, carbopol, peach flavour, and drinking water, and the ingredients in the agent are taken in a certain mass ratio.

EFFECT: invention provides good tolerability, comfortable use, avoidance of side effects, recovery of the physiological properties of the skin.

1 ex, 1 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions refers to pharmaceutical formulations and methods for preparing them of lipids for ophthalmological application containing a phospholipid ingredient containing natural zwitterion phospholipids, and an oil ingredient containing natural oil-in-water emulsions. The oil ingredient and phospholipid ingredient are preferentially related as 3:1; the phospholipid ingredient is found in the amount of 0.1%-5%, and the oil ingredient is found in the amount of 0.3%-15%.

EFFECT: group of inventions provides ocular drug delivery applicable for treating dry eye syndrome; it has an ability to recover the lipid lachrymal film layer, inhibits the inflammatory element observed.

37 cl, 19 tbl, 4 ex, 7 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to a method for preparing laevomycetin ointment with glutaric aldehyde and ethonium on the basis of modified laevomycetin, consisting in the fact that laevomycetin 100 mg/ml detoxified and polymerised at first in glutaric aldehyde 0.1-0.2% at 38-40C for 3-5 days, then in 0.2% ethonium at 38-40C for 2-3 days, is used for preparing 1-3% Vaseline ointment.

EFFECT: preparing the ointment with low toxicity and high bactericidal activity.

3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to a nanoemulsion as a carrier of a biologically active substance representing a DSIP or a herbal extract. The nanoemulsion contains water, a surfactant representing an ethylene oxide/ propylene oxide block copolymer, and a biopolymer in the form of mixed polysaccharide (PS) and polyaminosaccharide (PAS). The polysaccharide is 2-diethylaminoethyl-dextran or 3-dimethylaminopropyl-dextran. The polyaminosaccharide is chitosan or a chitosan derivative prepared by exhaustive alkylation of primary amino groups by glycidyl trimethylammonium chloride. The mass content of each of the polymers (ethylene oxide/ propylene oxide block copolymer, PS and PAS) in the mixture of polymers and nanoemulsion is found within the range of 0.1 to 0.7, while the ethylene oxide/ propylene oxide block copolymer concentration makes 0.4-4.0 g/l.

EFFECT: invention provides preparing the biologically compatible and storage-stable nanoemulsion.

2 cl, 7 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to pharmaceutical industry and represents applied for cosmetic or therapeutic purposes water composition in form of gel, based on hyaluronic acid or one of its salts, one or several polyols and lidocaine, subjected to thermal sterilisation, which results in its improved viscoelastic rheological properties and improved persistence in vivo, in which concentration of hyaluronic acid or one of its salts constitutes from 0.01 mg/ml to 100 mg/ml, molecular weight of hyaluronic acid or one of its salts constitutes from 1000 Dalton to 10106 Dalton, polyol concentration constitutes from 0.0001 to 100 mg/ml, and concentration of lidocaine constitutes from 0.0001 to 50 mg/ml.

EFFECT: invention ensures increase of physical-chemical stability of gels, based on hyaluronic acid, in order to increase duration of impact effect.

13 cl, 5 ex

Nanoemulsion // 2491917

FIELD: medicine.

SUBSTANCE: group of inventions refers to a nanoemulsion for active agent delivery, a method for preparing it, compositions containing it, and to using a nanoemulsion for preparing pharmaceutical compositions for local application and cosmetic compositions for skin application. The declared nanoemulstion contains a water ingredient and a carrier which contains a lipophilic ingredient in the amount of 0.1-15 wt %, a surfactant and isopropyl and/or 1-propyl alcohol. The average emulsified particle diameter makes less than 100 nm. The method for preparing the nanoemulsion involves mixing the water ingredient and carrier containing the lipophilic ingredient, surfactant and isopropyl and/or 1-propyl alcohol, for preparing the nanoemulsion at temperature 50-60C. The invention also refers to the composition for photodynamic therapy containing the above nanoemulsion and the active agent representing 5-aminolevulinic acid, a derivative, a precursor and/or a metabolite thereof. The above composition is applied to prepare the drug substance for photodynamic therapy and to treat senile keratosis. What is also declared is a diagnostic composition for detecting the dividing cells which contains the nanoemulsion and 5-aminolevulinic acid. The invention also refers to a kit for photodynamic therapy which comprises the composition for photodynamic therapy and one ingredient specified in a photoresist coating, an agent for attaching the above coating or an agent for applying the composition.

EFFECT: invention provides better stability and intensified cell and tissue penetration of the nanoemulsion.

25 cl, 6 dwg, 9 tbl, 5 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine and concerns a combined pharmaceutical composition having antibacterial activity. As an active substance, the composition contains a clindamycin salt or ester, a base which is a combination of a hydrophobic ingredient, a hydrophilic ingredient and an emulsifier, and a gelling polymer. A method of preparing the declared composition involves the fact that a solution of the clindamycin salt or ester in a part of the hydrophilic ingredient is added with the gelling polymer, then the emulsion prepared of a residual part of the hydrophilic ingredient, the hydrophobic ingredient and the emulsifier, and the prepared mixture is agitated until smooth.

EFFECT: new pharmaceutical formulation is characterised by a high level of antibacterial activity, stability both at storage temperature (25C), and at temperature of use (37C), good packaging extrusion.

15 cl, 1 dwg, 2 tbl, 4 ex

Up!